Esther Aguilar

Esther Aguilar

Auto-generated profile, based on publicly available information

Esther Aguilar

Department of Biochemistry and Molecular Biomedicine, Faculty of Biology, Universitat de Barcelona, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2016 in Stem Cells
Verified
Journal Article
Closed access
PDF file
EAEsther Aguilar
Esther Aguilar
IMIgor Marin de Mas
Igor Marin de Mas
EZErika Zodda
Erika Zodda
Silvia MarinSilvia Marin
Silvia Marin
FMFionnuala Morrish
Fionnuala Morrish
MCMARTA CASCANTE
MARTA CASCANTE

27 July 2018 in Science
Verified
Journal Article
Closed access
PDF file
MPM. C. Poffenberger
M. C. Poffenberger
AMA. Metcalfe-Roach
A. Metcalfe-Roach
EAE. Aguilar
E. Aguilar
JCJ. Chen
J. Chen
BHB. E. Hsu
B. E. Hsu
RJR. G. Jones
R. G. Jones
Inflammation promotes gut polyposis: Peutz–Jeghers Syndrome (PJS) causes benign polyps in the gut and a higher risk of several cancers caused by mutations in the tumor suppressor gene STK11 , which encodes liver kinase B1 (LKB1). LKB1's role in this disease is thought to be related to its tumor suppressor function. Now, Poffenberger et al. show that the T cell–specific heterozygous deletion of Stk11 is sufficient to reproduce PJS symptoms in mice (see the Perspective by Hollstein and Shaw). Polyps in mice and humans are characterized by immune cell infiltration, enhanced STAT3 signaling, and increased levels of inflammatory cytokines such as interleukin-6 (IL-6). Targeting STAT3 signaling, IL-6, or T cells ameliorated the polyps, suggesting potential therapies for this disease. Science , this issue p. 406 ; see also p. 332

6 July 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
SDSantiago Diaz-Moralli
Santiago Diaz-Moralli
EAEsther Aguilar
Esther Aguilar
Silvia MarinSilvia Marin
Silvia Marin
JCJohannes F. Coy
Johannes F. Coy
MDMieke Dewerchin
Mieke Dewerchin
MCMARTA CASCANTE
MARTA CASCANTE
A key role for transketolase-like 1 in tumor metabolic reprogramming

27 October 2017 in Diabetes
Verified
Journal Article
Closed access
PDF file
BBBenjamin Broche
Benjamin Broche
SFSelma Ben Fradj
Selma Ben Fradj
EAEsther Aguilar
Esther Aguilar
TSTiphaine Sancerni
Tiphaine Sancerni
MBMatthieu Bénard
Matthieu Bénard
BDBertrand Duvillié
Bertrand Duvillié
The mitochondrial carrier UCP2 belongs to the family of the uncoupling proteins. Despite its name, it is now accepted that UCP2 is rather a metabolite transporter than an uncoupling protein. UCP2 can regulate oxidative stress and/or energetic metabolism. In rodents, UCP2 is involved in the control of alpha- and beta-cell mass as well as insulin- and glucagon-secretion. Our aim was to determine whether the effects of UCP2 observed on beta-cell mass have an embryonic origin. Thus, we used Ucp2 knock-out mice. We found an increased size of the pancreas in Ucp2-/- fetuses at E16.5, associated with a higher number of alpha- and beta-cells. This phenotype was caused by an increase of PDX1+ progenitor-cells. Perinatally, an increase in the proliferation of endocrine cells also participates to their expansion. Next, we analyzed the oxidative stress in the pancreata. We quantified an increased nuclear translocation of NRF2 in the mutant suggesting an increased production of ROS. Phosphorylation of AKT, a ROS-target, was also activated in the Ucp2-/- pancreata. Finally, administration of the antioxidant N-acetyl-L-cysteine to Ucp2-/- pregnant mice alleviated the effect of knocking-out UCP2 on pancreas development. Together, these data demonstrate that UCP2 controls pancreas development through the ROS-AKT signaling pathway.

8 July 2011 in Metabolomics
Verified
Journal Article
Open access
PDF file
MZMiriam Zanuy
Miriam Zanuy
ARAntonio Ramos-Montoya
Antonio Ramos-Montoya
OVOscar Villacañas
Oscar Villacañas
NCNúria Canela
Núria Canela
AMAnibal Miranda
Anibal Miranda
MCMARTA CASCANTE
MARTA CASCANTE
Cyclin-dependent kinases CDK4 and CDK6 are essential for the control of the cell cycle through the G1 phase. Aberrant expression of CDK4 and CDK6 is a hallmark of cancer, which would suggest that CDK4 and CDK6 are attractive targets for cancer therapy. Herein, we report that calcein AM (the calcein acetoxymethyl-ester) is a potent specific inhibitor of CDK4 and CDK6 in HCT116 human colon adenocarcinoma cells, inhibiting retinoblastoma protein (pRb) phosphorylation and inducing cell cycle arrest in the G1 phase. The metabolic effects of calcein AM on HCT116 cells were also evaluated and the flux between the oxidative and non-oxidative branches of the pentose phosphate pathway was significantly altered. To elucidate whether these metabolic changes were due to the inhibition of CDK4 and CDK6, we also characterized the metabolic profile of a CDK4, CDK6 and CDK2 triple knockout of mouse embryonic fibroblasts. The results show that the metabolic profile associated with the depletion of CDK4, CDK6 and CDK2 coincides with the metabolic changes induced by calcein AM on HCT116 cells, thus confirming that the inhibition of CDK4 and CDK6 disrupts the balance between the oxidative and non-oxidative branches of the pentose phosphate pathway. Taken together, these results indicate that low doses of calcein can halt cell division and kill tumor cells. Thus, selective inhibition of CDK4 and CDK6 may be of greater pharmacological interest, since inhibitors of these kinases affect both cell cycle progression and the robust metabolic profile of tumors.

1 October 2014 in Future Medicinal Chemistry
Verified
Journal Article
Closed access
IMIgor Marín de Mas
Igor Marín de Mas
EAEsther Aguilar
Esther Aguilar
AJAnusha Jayaraman
Anusha Jayaraman
IPIbrahim H Polat
Ibrahim H Polat
AMAlfonso Martín-Bernabé
Alfonso Martín-Bernabé
MCMARTA CASCANTE
MARTA CASCANTE
Metabolic processes are altered in cancer cells, which obtain advantages from this metabolic reprogramming in terms of energy production and synthesis of biomolecules that sustain their uncontrolle...